EUVIMEDEUVIMED entdecken
Fallbericht

TB Anywhere, TB Everywhere. The First Case of pre-Extensively Drug Resistant Tuberculosis Treated with BPaL in Italy: Challenges and Opportunities for Transborder Collaboration

Giovanni Fumagalli iD, Niccolò Riccardi, Gaia Catalano, Maurizio Ferrarese, Alice Claudia Repossi, Luigi R Codecasa

Microbial Drug Resistance · 2025

DOI: 10.1089/mdr.2024.0045 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Microbial Drug Resistance, 2025. Verfasst von Giovanni Fumagalli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regional TB Reference Centre, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. Hauptthemen laut MEDLINE: Antitubercular Agents, Extensively Drug-Resistant Tuberculosis, Linezolid, Mycobacterium tuberculosis. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Even if in the past years new effective, safe, and orally administrable drugs are available to create shorter regimens, drug-resistant (DR) tuberculosis (TB) treatment remains a critical issue and a major challenge faced by clinicians worldwide. We present the first case of transborder pulmonary pre-extensively drug-resistant (pre-XDR)-TB treated in Italy with the bedaquiline-pretomanid-linezolid regimen. Diagnosis and treatment were started in Ukraine, and, after a month of treatment, due to the Russo-Ukrainian war, the patient moved to Italy, where the diagnosis was confirmed both by genotypic and phenotypic drug susceptibility tests, and treatment continued. In this short report, we highlight challenges and future opportunities to improve the clinical management of patient with DR-TB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsExtensively Drug-Resistant TuberculosisLinezolidMycobacterium tuberculosisHumansDiarylquinolinesDrug Therapy, CombinationGenotypeItalyMicrobial Sensitivity TestsTuberculosis, Multidrug-ResistantUkraineNitroimidazoles

Stichwörter der Autor:innen

EuropeTB treatmentpre-XDR-TBtransborder

Substanzen

Antitubercular AgentsDiarylquinolinesLinezolidbedaquilinepretomanidNitroimidazoles

Autor:innen und Institutionen

  • Regional TB Reference Centre, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • StopTB Italia ODV, Milan, Italy.
  • Department of Physiopathology and Transplantation, UniversitàdegliStudi di Milano, Milan, Italy.
  • Infectious Diseases Unit, AziendaOspedaliero-Universitaria Pisana, Pisa, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

ORCID-Profile: Giovanni Fumagalli

Zitieren

APA

Fumagalli, G., Riccardi, N., Catalano, G., Ferrarese, M., Repossi, A. C., & Codecasa, L. R. (2025). TB Anywhere, TB Everywhere. The First Case of pre-Extensively Drug Resistant Tuberculosis Treated with BPaL in Italy: Challenges and Opportunities for Transborder Collaboration. Microbial Drug Resistance. https://doi.org/10.1089/mdr.2024.0045

Vancouver

Fumagalli G, Riccardi N, Catalano G, Ferrarese M, Repossi AC, Codecasa LR. TB Anywhere, TB Everywhere. The First Case of pre-Extensively Drug Resistant Tuberculosis Treated with BPaL in Italy: Challenges and Opportunities for Transborder Collaboration. Microbial Drug Resistance. 2025. doi:10.1089/mdr.2024.0045

BibTeX
@article{Fumagalli2025,
  author = {Fumagalli, Giovanni and Riccardi, Niccolò and Catalano, Gaia and Ferrarese, Maurizio and Repossi, Alice Claudia and Codecasa, Luigi R},
  title = {TB Anywhere, TB Everywhere. The First Case of pre-Extensively Drug Resistant Tuberculosis Treated with BPaL in Italy: Challenges and Opportunities for Transborder Collaboration},
  journal = {Microbial Drug Resistance},
  year = {2025},
  doi = {10.1089/mdr.2024.0045}
}
Kostenlos starten →